FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912373630> ?p ?o ?g. }

• W2912373630 endingPage "1611" @default.
• W2912373630 startingPage "1611" @default.
• W2912373630 abstract "Abstract Background: The paradigm of the treatment mantle cell lymphoma (MCL) has changed due to development of newer agents (such as ibrutinib, lenalidomide, temsirolimus). Considering that the scheme of using the newer drugs implies permanent drug intake (before disease progression), which helps prevent the early relapses. With a high degree of probability, it can be assumed that MCL, in the future can be withdrawn from the group of aggressive and relapsing lymphomas. Evaluation and monitoring of the minimal residual disease (MRD) in patients with MCL allows to predict the course of the disease and optimize the strategy for maintaining this category of patients. Aim: To assess influence of MRD negative (MRDneg) status on the duration of progression free survival (PFS) and overall survival (OS). Method: In this study were included 33 patients with MCL (male/female ratio 3:1), age 51 to 82 years (median 64 years). The median of follow-up duration is 80.7 months (range 0.7-147.1). Median of therapy lines - 1 (range 1-5). With rituximab-containing chemotherapy regimens were treated 25 patients (R-CHOP - 12, RFC - 5, RBV - 3, RB - 2, R-DHAP - 1, R-Hyper-CVAD - 1, RVc-CAP - 1); ibrutinib - 3, lenalidomide - 3 and temsirolimus - 1. Autologous stem cell transplantation (AutoSCT) was performed in 7 patients (21.2%). Maintenance therapy received 23 patients (69.7%): rituximab - 20, ibrutinib - 1, lenalidomide - 1 and temsirolimus - 1. During the follow-up period, 9 patients (27.2%) died: progression of the disease - 5, other reasons - 4. The evaluation of MRD status was carried out using 5-color flow cytometry on bone marrow samples after completion of induction therapy. The absent of MRD was detected when less than 1 tumor cell was detected per 10000 leukocytes (10-4). Results: Complete remission (CR) was achieved in 54.5% (n=18), partial remission (PR) - 45.5% (n=15). Patients were divided into two groups depending on MRD status: group MRD positive (MRDpos) (n=12) and group MRD negative (MRDneg) (n=21). The frequency of achievement of MRDneg status was 63.6% (CR - n=15, PR - n=6). Noted, that all patients (n=7) who underwent AutoSCT achieved MRDneg status after induction therapy and kept it after consolidation with AutoSCT. Disease progression in MRDpos group was state in 11 patients (91.7%), in MRDneg group - 6 (28.6%) (р=0.0005). Patients with MRDpos status who underwent maintenance therapy achieved MRDneg status in 8/12 cases. One patient, after completion R-CHOP + AutoSCT followed by a two-year maintenance program of rituximab, retained MRDneg status. A year later, during the control survey, MRDpos status was recorded. This patient was resumed maintenance therapy with rituximab. MRDneg status is achieved after 6 months from the beginning of maintenance therapy. Median PFS in group MRDneg was not achieved, in group MRDpos - 12.5 months (р=0.001). Medians OS were not achieved in both groups. 5-year OS were: group MRDneg - 83.8% and group MRDpos - 73.3%. 10-year OS were: group MRDneg - 64.4% and group MRDpos - 58.7%. When comparing OS in patients among all groups no significant differences were found, which is probably due to a small number of events (р>0.05). Conclusion: Our data demonstrate that achievement MRDneg remissions determine duration of response on ongoing therapy and significant increase of PFS duration. Presently, MRD detection in patients with MCL is important part of complex assessment of effectiveness therapy and it need to be studied more. Figure. Figure. Disclosures No relevant conflicts of interest to declare." @default.
• W2912373630 created "2019-02-21" @default.
• W2912373630 creator A5002759045 @default.
• W2912373630 creator A5013794624 @default.
• W2912373630 creator A5026965940 @default.
• W2912373630 creator A5046033918 @default.
• W2912373630 creator A5054098489 @default.
• W2912373630 creator A5061877238 @default.
• W2912373630 creator A5075397889 @default.
• W2912373630 creator A5076006575 @default.
• W2912373630 creator A5077933082 @default.
• W2912373630 date "2018-11-29" @default.
• W2912373630 modified "2023-09-27" @default.
• W2912373630 title "Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma" @default.
• W2912373630 doi "https://doi.org/10.1182/blood-2018-99-119761" @default.
• W2912373630 hasPublicationYear "2018" @default.
• W2912373630 type Work @default.
• W2912373630 sameAs 2912373630 @default.
• W2912373630 citedByCount "0" @default.
• W2912373630 crossrefType "journal-article" @default.
• W2912373630 hasAuthorship W2912373630A5002759045 @default.
• W2912373630 hasAuthorship W2912373630A5013794624 @default.
• W2912373630 hasAuthorship W2912373630A5026965940 @default.
• W2912373630 hasAuthorship W2912373630A5046033918 @default.
• W2912373630 hasAuthorship W2912373630A5054098489 @default.
• W2912373630 hasAuthorship W2912373630A5061877238 @default.
• W2912373630 hasAuthorship W2912373630A5075397889 @default.
• W2912373630 hasAuthorship W2912373630A5076006575 @default.
• W2912373630 hasAuthorship W2912373630A5077933082 @default.
• W2912373630 hasConcept C126322002 @default.
• W2912373630 hasConcept C141071460 @default.
• W2912373630 hasConcept C143998085 @default.
• W2912373630 hasConcept C183713625 @default.
• W2912373630 hasConcept C185592680 @default.
• W2912373630 hasConcept C190283241 @default.
• W2912373630 hasConcept C2776063141 @default.
• W2912373630 hasConcept C2776364478 @default.
• W2912373630 hasConcept C2776694085 @default.
• W2912373630 hasConcept C2776820818 @default.
• W2912373630 hasConcept C2777478702 @default.
• W2912373630 hasConcept C2777525834 @default.
• W2912373630 hasConcept C2777938653 @default.
• W2912373630 hasConcept C2778461978 @default.
• W2912373630 hasConcept C2779050716 @default.
• W2912373630 hasConcept C2779338263 @default.
• W2912373630 hasConcept C2779823535 @default.
• W2912373630 hasConcept C2779878957 @default.
• W2912373630 hasConcept C2780007613 @default.
• W2912373630 hasConcept C2780653079 @default.
• W2912373630 hasConcept C2780739268 @default.
• W2912373630 hasConcept C2911091166 @default.
• W2912373630 hasConcept C55493867 @default.
• W2912373630 hasConcept C71924100 @default.
• W2912373630 hasConcept C75217442 @default.
• W2912373630 hasConceptScore W2912373630C126322002 @default.
• W2912373630 hasConceptScore W2912373630C141071460 @default.
• W2912373630 hasConceptScore W2912373630C143998085 @default.
• W2912373630 hasConceptScore W2912373630C183713625 @default.
• W2912373630 hasConceptScore W2912373630C185592680 @default.
• W2912373630 hasConceptScore W2912373630C190283241 @default.
• W2912373630 hasConceptScore W2912373630C2776063141 @default.
• W2912373630 hasConceptScore W2912373630C2776364478 @default.
• W2912373630 hasConceptScore W2912373630C2776694085 @default.
• W2912373630 hasConceptScore W2912373630C2776820818 @default.
• W2912373630 hasConceptScore W2912373630C2777478702 @default.
• W2912373630 hasConceptScore W2912373630C2777525834 @default.
• W2912373630 hasConceptScore W2912373630C2777938653 @default.
• W2912373630 hasConceptScore W2912373630C2778461978 @default.
• W2912373630 hasConceptScore W2912373630C2779050716 @default.
• W2912373630 hasConceptScore W2912373630C2779338263 @default.
• W2912373630 hasConceptScore W2912373630C2779823535 @default.
• W2912373630 hasConceptScore W2912373630C2779878957 @default.
• W2912373630 hasConceptScore W2912373630C2780007613 @default.
• W2912373630 hasConceptScore W2912373630C2780653079 @default.
• W2912373630 hasConceptScore W2912373630C2780739268 @default.
• W2912373630 hasConceptScore W2912373630C2911091166 @default.
• W2912373630 hasConceptScore W2912373630C55493867 @default.
• W2912373630 hasConceptScore W2912373630C71924100 @default.
• W2912373630 hasConceptScore W2912373630C75217442 @default.
• W2912373630 hasIssue "Supplement 1" @default.
• W2912373630 hasLocation W29123736301 @default.
• W2912373630 hasOpenAccess W2912373630 @default.
• W2912373630 hasPrimaryLocation W29123736301 @default.
• W2912373630 hasRelatedWork W2145751461 @default.
• W2912373630 hasRelatedWork W2516086162 @default.
• W2912373630 hasRelatedWork W2564917882 @default.
• W2912373630 hasRelatedWork W2613415189 @default.
• W2912373630 hasRelatedWork W2790959278 @default.
• W2912373630 hasRelatedWork W2889080550 @default.
• W2912373630 hasRelatedWork W2912373630 @default.
• W2912373630 hasRelatedWork W2954035736 @default.
• W2912373630 hasRelatedWork W2972330211 @default.
• W2912373630 hasRelatedWork W4251767133 @default.
• W2912373630 hasVolume "132" @default.
• W2912373630 isParatext "false" @default.
• W2912373630 isRetracted "false" @default.
• W2912373630 magId "2912373630" @default.
• W2912373630 workType "article" @default.